Skip to main content
    B

    Bicycle Therapeutics Ltd (BCYC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.18
    -0.19 (-5.64%)

    Market Cap: $236.22M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Bicycle Therapeutics Ltd (BCYC) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Bicycle Therapeutics (BCYC) to earn -$2.26 per share in the fiscal year ending Dec 31, 2026, on revenue of $38.04M. Of 9 analysts, 6 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.11, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.

    RatingAnalystsShare
    Strong Buy222.2%
    Buy444.4%
    Hold333.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    9

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 81.7%.

    Fiscal year ending Dec 31, 2026
    -$2.26
    EPS consensus, revenue $38.04M
    Fiscal year ending Dec 31, 2027
    -$2.33
    EPS consensus, revenue $6.95M
    Fiscal year ending Dec 31, 2028
    -$2.17
    EPS consensus, revenue $27.21M
    Next report
    Mar 15, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.26-$2.45 to -$2.048$38.04M$35.77M to $50.00M9
    Dec 31, 2027-$2.33-$2.94 to -$1.489$6.95MN/A9
    Dec 31, 2028-$2.17-$3.06 to -$1.296$27.21M$26.76M to $27.65M9

    Quarterly Estimates

    The EPS consensus falls from -$0.44 for the quarter ending Dec 31, 2026 to -$0.61 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.44-$0.64 to $0.3312$1.86M$539000 to $6.30M11
    Mar 31, 2027-$0.61-$0.65 to -$0.553$1.07MN/A4

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202711
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.61.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$2.26-$2.26-$2.45-$2.45-$2.61N/A
    Fiscal year ending Dec 31, 2027-$2.33-$2.32-$2.22-$2.22-$2.22N/A
    Quarter ending Mar 31, 2027-$0.61-$0.59-$0.59-$0.59-$0.59N/A

    Frequently Asked Questions About BCYC

    What is the BCYC stock forecast?

    Consensus analyst estimates put Bicycle Therapeutics's EPS at -$2.26 for the fiscal year ending Dec 31, 2026, on revenue of $38.04M. The consensus rating from 9 analysts is Buy.

    How do analysts rate BCYC stock?

    Of 9 analysts covering Bicycle Therapeutics, 2 rate it Strong Buy, 4 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from BCYC next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.26, with estimates from -$2.45 to -$2.04 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.33, with estimates from -$2.94 to -$1.48 from 9 analysts.

    What revenue do analysts expect from Bicycle Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $38.04M, with estimates from $35.77M to $50.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.95M.

    How many analysts cover BCYC?

    9 analysts rate Bicycle Therapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.